Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ¾ÏÄ¡·á > ¾ÏÄ¡·áÀÇ Ç×Ç÷°ü Çü¼ºÁ¦ ¿¬±¸ °³¹ß : °æÇÕ µ¿Çâ
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4556)
°¨¿°Áúȯ (322)
°ñÁúȯ Ä¡·á (48)
´ç´¢º´ (164)
¹é½Å (171)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (49)
ºñó¹æ ÀǾàǰ (149)
¼öÀÇÇÐ (18)
½Å°æÁúȯ (180)
½Å¾à°³¹ß (1333)
¾ÏÄ¡·á (857)
¾à¹°Àü´Þ (179)
ÀǾàǰ ±ÔÁ¦È¯°æ (108)
Á¤½ÅÁúȯ (89)
Á¦³×¸¯ ÀǾàǰ (117)
Á¦¾àȸ»çºÐ¼® (490)
󹿾à (128)
½ÃÀ庸°í¼­

¾ÏÄ¡·áÀÇ Ç×Ç÷°ü Çü¼ºÁ¦ ¿¬±¸ °³¹ß : °æÇÕ µ¿Çâ

Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology

¸®¼­Ä¡»ç BioSeeker Group AB
¹ßÇàÀÏ 2008³â 03¿ù »óǰÄÚµå 63840
ÆäÀÌÁö Á¤º¸ 231 pages
°¡°Ý
US $ 3,553 £Ü 4,034,400 PDF by E-mail (Single User License)


BioSeeker Group AB ¿¡¼­ 2008³â 03¿ù ¿¡ ¹ßÇàÇÑ ¡¸¾ÏÄ¡·áÀÇ Ç×Ç÷°ü Çü¼ºÁ¦ ¿¬±¸ °³¹ß : °æÇÕ µ¿Ç⡹ º¸°í¼­´Â 231 pages·Î ±¸¼ºµÇ¾î, US $3,553 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

¾ÏÄ¡·áÀÇ Ç×Ç÷°ü Çü¼ºÁ¦ ¿¬±¸ °³¹ßÀÇ 88°³ Ç¥ÀûÄ¡·áÁ¦¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù.

  • Á¦1Àå °³¿ä
  • Á¦2Àå ¾Ï¿¡ ´ëÇÏ¿©
  • Á¦3Àå ¹æ¹ý·Ð
  • Á¦4Àå ¸ñÂ÷
  • Á¦5Àå º» º¸°í¼­ÀÇ ÀÌ¿ë ¹æ¹ý
  • Á¦6Àå Ç×Ç÷°ü Çü¼ºÁ¦ È­ÇÕ¹°ÀÇ Á¾·ù ¹× Ç¥ÀûÀÇ ¼­ºê¼¿·ê·¯(Sub-cellular) ±¹¼ÒÈ­
  • Á¦7Àå ¾Ï °Ô³ð ÇÁ·ÎÁ§Æ®¿Í Ç×Ç÷°ü Çü¼ºÁ¦ Ç¥Àû
  • Á¦8Àå »ç¶÷ÀÇ Ç×Ç÷°ü Çü¼ºÁ¦ Ç¥Àû ÇÁ·ÎÅ×ÀÎ ¹ßÇö ÇÁ·ÎÆÄÀÏ
  • Á¦9Àå Ç×Ç÷°ü Çü¼ºÁ¦ÀÇ °æ·Î ºÐ¼®
  • Á¦10Àå Æ¯Á¤ Ç×Ç÷°ü Çü¼ºÁ¦ Ç¥ÀûÀÇ ÇÁ·ÎÅ×Àγ¢¸® »óÈ£ÀÛ¿ë
  • Á¦11Àå Ç×Ç÷°ü Çü¼ºÁ¦ Ç¥Àû¿¡¼­ ¾òÀ» ¼ö ÀÖ´Â »ý¹°ÇÐÀû µ¥ÀÌÅÍ
  • Á¦12Àå ¾ÏÀÇ Ç×Ç÷°ü Çü¼ºÁ¦ Ç¥Àû ÇÁ·ÎÆÄÀÏ
  • Á¦13Àå Ç×Ç÷°ü Çü¼ºÁ¦ÀÇ Ä¡·áÁ¦¤ýÇÁ·ÎÅ×ÀÎ »óÈ£ÀÛ¿ë(Protein Interactome)
  • Á¦14Àå Ç×Ç÷°ü Çü¼ºÁ¦ Ç¥ÀûÀÇ ÁøÇà ¹× ¼º¼÷µµ
  • Á¦15Àå ¾ÏÀÇ Àû¿ëº° Ç×Ç÷°ü Çü¼ºÁ¦ Ç¥Àû È¥ÇÕ
  • Á¦16Àå ±â¾÷º° Ç×Ç÷°ü Çü¼ºÁ¦¿Í Ç¥Àû
  • Á¦17Àå ¸éÃ¥ »çÇ×
  • Á¦18Àå Ä¡·áÁ¦ À妽º
  • Á¦19Àå ±â¾÷ À妽º
  • µµÇ¥
pmh
Back to Top